Myochrysine
New Arthritis Drug Xeljanz Gets FDA Approval »
"Nov. 6, 2012 -- The FDA has approved Pfizer's Xeljanz (tofacitinib), a first-of-its-kind treatment for rheumatoid arthritis.
Xeljanz is approved for use by patients not helped by methotrexate, the usual first treatment for RA. It's a "...
Read the New Arthritis Drug Xeljanz Gets FDA Approval article »
Myochrysine
CONTRAINDICATIONS
Hypersensitivity to any component of this product.
Severe toxicity resulting from previous exposure to gold or other heavy metals.
Severe debilitation.
Systemic lupus erythematosus.
Last reviewed on RxList: 11/25/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Myochrysine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Arthritis
Get the latest treatment options
Updated & New
